| __timestamp | Bausch Health Companies Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 246000000 | 9086000000 |
| Thursday, January 1, 2015 | 582800000 | 8935000000 |
| Friday, January 1, 2016 | 455000000 | 9039000000 |
| Sunday, January 1, 2017 | 366000000 | 8972000000 |
| Monday, January 1, 2018 | 414000000 | 9074000000 |
| Tuesday, January 1, 2019 | 471000000 | 9402000000 |
| Wednesday, January 1, 2020 | 452000000 | 8980000000 |
| Friday, January 1, 2021 | 465000000 | 9540000000 |
| Saturday, January 1, 2022 | 529000000 | 9996000000 |
| Sunday, January 1, 2023 | 604000000 | 11371000000 |
Cracking the code
In the competitive landscape of pharmaceuticals, strategic investment in research and development (R&D) is crucial. Over the past decade, Novartis AG has consistently outpaced Bausch Health Companies Inc. in R&D spending. From 2014 to 2023, Novartis's R&D expenses have grown by approximately 25%, peaking at over $11 billion in 2023. In contrast, Bausch Health's R&D investment increased by nearly 145% during the same period, reaching $604 million in 2023.
Novartis's commitment to innovation is evident, with annual R&D spending averaging around $9.4 billion. This robust investment underscores their strategic focus on pioneering medical breakthroughs. Meanwhile, Bausch Health, despite its smaller scale, has shown a commendable upward trend in R&D allocation, reflecting its ambition to enhance its competitive edge.
These trends highlight the differing strategic priorities of these pharmaceutical giants, with Novartis leading the charge in R&D investment.
Research and Development Investment: Eli Lilly and Company vs Bausch Health Companies Inc.
R&D Insights: How Novartis AG and Iovance Biotherapeutics, Inc. Allocate Funds
Research and Development Investment: Sanofi vs Bausch Health Companies Inc.
Regeneron Pharmaceuticals, Inc. or Bausch Health Companies Inc.: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for argenx SE and Bausch Health Companies Inc.
Research and Development Investment: Teva Pharmaceutical Industries Limited vs Bausch Health Companies Inc.
R&D Spending Showdown: Viking Therapeutics, Inc. vs Bausch Health Companies Inc.
Research and Development: Comparing Key Metrics for CRISPR Therapeutics AG and Bausch Health Companies Inc.
Research and Development Expenses Breakdown: Rhythm Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Analyzing R&D Budgets: Veracyte, Inc. vs Bausch Health Companies Inc.
R&D Insights: How ACADIA Pharmaceuticals Inc. and Bausch Health Companies Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.